CLCN2
Chloride channel protein 2
As of the edition of 20 October 2026, CLCN2 (chloride channel protein 2, UniProt P51788) has 2 drugs tested at it and 1 company on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P51788
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 8
- Disease areas
- Digestive system; Chemically induced; Mental health; Cancer; Immune system; Bones, joints and muscles; Hormones; Inherited and neonatal
- Registered trials of its drugs
- 39
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lubiprostone | Marketed | Phase 4 | none listed |
| Cobiprostone | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Byk-Mallinckrodt CIL | Route B |
The other 0 companies at CLCN2
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at CLCN2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.